LU91162I2 - Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables. - Google Patents

Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables.

Info

Publication number: LU91162I2
Authority: LU; Luxembourg
Prior art keywords: alkyl; amino; alkoxy; halogen; optionally substituted
Prior art date: 1989-11-28

Application number

LU91162C

Other languages

English (en)

Original Assignee

Roche Palo Alto Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-28

Filing date

2005-04-18

Publication date

2005-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23755479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91162(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-18 Application filed by Roche Palo Alto Llc filed Critical Roche Palo Alto Llc

2005-06-20 Publication of LU91162I2 publication Critical patent/LU91162I2/fr

Links

125000000217 alkyl group Chemical group 0.000 abstract 6
125000003545 alkoxy group Chemical group 0.000 abstract 3
229910052736 halogen Inorganic materials 0.000 abstract 3
150000002367 halogens Chemical class 0.000 abstract 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
-1 nitro, amino, amino carbonyl Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000000168 pyrrolyl group Chemical group 0.000 abstract 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Saccharide Compounds (AREA)

LU91162C 1989-11-28 2005-04-18 Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables. LU91162I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US44208289A	1989-11-28	1989-11-28

Publications (1)

Publication Number	Publication Date
LU91162I2 true LU91162I2 (fr)	2005-06-20

Family

ID=23755479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91162C LU91162I2 (fr)	1989-11-28	2005-04-18	Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables.

Country Status (23)

Country	Link
US (1)	US5202333A (fr)
EP (1)	EP0430190B1 (fr)
JP (1)	JPH0662607B2 (fr)
KR (1)	KR970007917B1 (fr)
AT (1)	ATE124698T1 (fr)
AU (1)	AU642178B2 (fr)
BR (1)	BR1100680A (fr)
CA (1)	CA2030718C (fr)
DE (2)	DE69020694T2 (fr)
DK (1)	DK0430190T3 (fr)
ES (1)	ES2075121T3 (fr)
FI (1)	FI98367C (fr)
HK (1)	HK36097A (fr)
HU (1)	HU218654B (fr)
IE (1)	IE68434B1 (fr)
IL (2)	IL96486A (fr)
LU (1)	LU91162I2 (fr)
NL (1)	NL300194I1 (fr)
NO (2)	NO175309C (fr)
NZ (1)	NZ236225A (fr)
PL (3)	PL166267B1 (fr)
PT (1)	PT96001B (fr)
ZA (1)	ZA909529B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL166267B1 (pl) *	1989-11-28	1995-04-28	Syntex Inc	Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
US5491148A (en) *	1991-04-26	1996-02-13	Syntex (U.S.A.) Inc.	Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
DE69231395T3 (de)	1991-09-20	2005-07-21	Glaxo Group Ltd., Greenford	Neue medizinische Indikation für Tachykinin-Antagonisten
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
EP0679088B1 (fr) *	1992-09-29	2002-07-10	Inhale Therapeutic Systems	Liberation dans les poumons de fragments actifs d'hormone parathyroidienne
ATE416755T1 (de) *	1994-03-07	2008-12-15	Nektar Therapeutics	Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US20030113273A1 (en) *	1996-06-17	2003-06-19	Patton John S.	Methods and compositions for pulmonary delivery of insulin
GB2288732B (en) *	1994-04-13	1998-04-29	Quadrant Holdings Cambridge	Pharmaceutical compositions
MX9605717A (es) *	1994-05-18	1998-05-31	Inhale Therapeutic Syst	Metodos y composiciones para la formulacion de polvo seco de interferones.
US5567818A (en) *	1994-07-08	1996-10-22	Syntex (U.S.A.) Inc.	Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
US5510486A (en) *	1994-07-26	1996-04-23	Syntex (U.S.A.) Inc.	Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5492914A (en) *	1994-07-28	1996-02-20	Syntex (U.S.A.) Inc.	2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
US6290991B1 (en) *	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US5723103A (en) *	1994-12-09	1998-03-03	Vanderbilt University	Substituted benzamides and radioligand analogs and methods of use
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
AU3422800A (en) *	1999-02-18	2000-09-04	Novartis Ag	Use of 5-ht3 receptor antagonists
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt)	2000-05-10	2014-12-16	Novartis Ag	Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20050042194A1 (en)	2000-05-11	2005-02-24	A.P. Pharma, Inc.	Semi-solid delivery vehicle and pharmaceutical compositions
EP1284732A2 (fr) *	2000-05-18	2003-02-26	Glaxo Group Limited	Methode de traitement de la dyspepsie fonctionnelle
US7067148B2 (en)	2001-02-15	2006-06-27	King Pharmaceutical Research & Development, Inc.	Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
PT1458360E (pt)	2001-12-19	2011-07-13	Novartis Ag	Derivados de indole como agonistas do recetor s1p1
WO2003072578A1 (fr) *	2002-02-20	2003-09-04	Pharmacia & Upjohn Company	Composes azabicycliques presentant une activite de recepteurs d'alfa 7 nicotinique acetylcholine
US20030187017A1 (en) *	2002-11-14	2003-10-02	Mangel Allen Wayne	Method for treating functional dyspepsia
DE10393729T5 (de) *	2002-11-15	2005-10-13	Helsinn Healthcare S.A.	Verfahren zur Behandlung von Emesis
JO2735B1 (en) *	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en)	2003-01-30	2013-12-03	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
MY143789A (en) *	2003-02-18	2011-07-15	Helsinn Healthcare Sa	Use of palonosetron treating post- operative nausea and vomiting
US20060167072A1 (en) *	2004-01-30	2006-07-27	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
CN100336508C (zh) *	2005-02-23	2007-09-12	重庆医药工业研究院有限责任公司	一种稳定的帕洛诺司琼注射液
US20070031342A1 (en) *	2005-06-22	2007-02-08	Nektar Therapeutics	Sustained release microparticles for pulmonary delivery
US20080004260A1 (en) *	2006-06-29	2008-01-03	Transcept Pharmaceuticals, Inc.	Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8614225B2 (en) *	2006-08-30	2013-12-24	Dr. Reddy's Laboratories Limited	Process for the purification of palonosetron or its salt
EP2103612A1 (fr)	2006-10-23	2009-09-23	Sicor, Inc.	Formules cristallines d'hydrochlorure de palonosétron
KR101441459B1 (ko) *	2006-10-24	2014-09-18	헬신 헬쓰케어 에스.에이.	안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
JP2010512333A (ja) *	2006-12-07	2010-04-22	ヘルシンヘルスケアソシエテアノニム	塩酸パロノセトロンの結晶及び非晶質形
WO2008146283A2 (fr) *	2007-05-29	2008-12-04	Chemagis Ltd.	Nouveaux sels de palonosétron et procédés pour la préparation et la purification de ceux-ci
US20090227623A1 (en) *	2007-09-15	2009-09-10	Protia, Llc	Deuterium-enriched palosetron
CN101157691B (zh) *	2007-10-18	2011-01-12	杭州九源基因工程有限公司	一种盐酸帕洛诺司琼的生产工艺
AR069625A1 (es)	2007-12-13	2010-02-03	Glenmark Generics Ltd	Base libre de palonosetron y procedimiento para su preparacion
WO2009087643A1 (fr) *	2008-01-11	2009-07-16	Natco Pharma Limited	Nouvelles formes cristallines du chlorhydrate de palonosétron
WO2009136405A1 (fr) *	2008-05-05	2009-11-12	Natco Pharma Limited	Palonosétron de pureté élevée et ses caractéristiques à l’état solide
US20100048607A1 (en) *	2008-08-25	2010-02-25	Chandrashekhar Kocherlakota	Formulations comprising palonosetron
US20100099701A1 (en) *	2008-10-20	2010-04-22	Auspex Pharmaceuticals, Inc.	Isoquinolinone modulators of 5-ht3 receptors
WO2010056656A2 (fr) *	2008-11-11	2010-05-20	Dr. Reddy's Laboratories Ltd.	Synthèse de chlorhydrate de palonosétron cristallin
EP2364138A2 (fr)	2008-12-08	2011-09-14	Teva Pharmaceutical Industries Ltd.	Formulation de palonosétron
MX2011006265A (es) *	2008-12-11	2012-06-28	A P Pharma Inc	Metodos para mejorar la estabilidad de poliortoesteres y sus formulaciones.
CN101849904A (zh) *	2009-04-03	2010-10-06	南京长澳医药科技有限公司	一种帕洛诺司琼注射液及其制备方法
CN101851233B (zh) *	2009-04-03	2013-03-06	四川滇虹医药开发有限公司	盐酸帕洛诺司琼和其前体化合物及制备
US20100298397A1 (en) *	2009-05-19	2010-11-25	Singh Nikhilesh N	Method of treatment of obsessive compulsive disorder with ondansetron
ES2432618T3 (es)	2009-05-20	2013-12-04	Inserm (Institut National De La Santé Et De La Recherche Medicale)	Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
DK2432467T3 (en)	2009-05-20	2018-04-16	Inst Nat Sante Rech Med	SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN TREATMENT OF VESTIBULAR DAMAGE LESSONS
WO2011001400A2 (fr)	2009-06-30	2011-01-06	Ranbaxy Laboratories Limited	Procédés de préparation des formes i et ii de l'hydrochlorure de palonosétron
WO2011008572A2 (fr)	2009-07-14	2011-01-20	Albany Molecular Research, Inc.	Modulateurs du récepteur 5-ht3, procédés de fabrication et d'utilisation de ceux-ci
WO2011013095A1 (fr)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Procédés de préparation du palonosétron
CN102781939A (zh) *	2009-11-13	2012-11-14	赫尔辛医疗股份公司	帕洛诺司琼代谢物
EP2722045B1 (fr)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions pour traiter les nausées et vomissements à médiation centrale
ES2623503T3 (es)	2009-11-18	2017-07-11	Helsinn Healthcare Sa	Composiciones para tratar náuseas y vómitos mediados centralmente
CN105412110B (zh)	2011-10-18	2018-05-25	赫尔森保健股份公司	奈妥匹坦和帕洛诺司琼的治疗性组合
CN102688185B (zh) *	2012-06-01	2013-07-10	齐鲁制药(海南)有限公司	一种稳定的帕洛诺司琼注射液及其制备方法
CN105934247A (zh)	2013-12-23	2016-09-07	株式会社三养生物制药	包含帕洛诺司琼的药物组合物
CA2996717A1 (fr)	2015-09-11	2017-03-16	Chase Pharmaceuticals Corporation	Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du systeme nerveux central
CA3025837C (fr) *	2016-06-06	2024-02-13	Helsinn Healthcare Sa	Formulations injectables physiologiquement equilibrees de fosnetupitant
CN110719778B (zh)	2017-04-24	2024-06-18	才思治疗公司	用于治疗抑郁的组合物和方法
EP3672964A4 (fr)	2017-08-21	2021-05-26	Leiutis Pharmaceuticals Pvt. Ltd.	Nouvelles formulations à triple combinaison pour une thérapie antiémétique
EP4633608A1 (fr)	2022-12-12	2025-10-22	Alfred E. Tiefenbacher (GmbH & Co. KG)	Association de dose fixe sans antioxydant de netupitant et de palonosétron
WO2024126398A1 (fr)	2022-12-12	2024-06-20	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Combinaison de doses fixes comprenant du netupitant et du palonosétron
EP4385497A1 (fr)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Combinaison de doses fixes sans antioxydant de nétupitant et de palonosétron
EP4385500A1 (fr)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Combinaison de doses fixes comprenant du nétupitant et du palonosétron

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3341528A (en) *	1963-11-07	1967-09-12	Warner Lambert Pharmaceutical	Substituted benzoquinolines
US3896132A (en) *	1969-08-19	1975-07-22	Hoffmann La Roche	Process for preparing 1,2,3,8,9,9a-hexahydro-5,6-dialkoxy-1-alkyl-benzo(d,e)quinolin-7-ore compounds
US4309543A (en) *	1980-03-17	1982-01-05	Dynapol	Process for preparing cyclic amides
EP0093488A3 (fr) *	1982-03-18	1984-05-23	Beecham Group Plc	Composés nortropyl benzopyrrolinoniques, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4571396A (en) *	1984-04-16	1986-02-18	Warner-Lambert Company	Antibacterial agents
WO1988004292A1 (fr) *	1986-12-11	1988-06-16	The Upjohn Company	Amino-polyhydro-benzo-(iso)quinoleines a proprietes antipsychotiques et produits intermediaires
EP0315390B1 (fr) *	1987-11-04	1994-07-20	Beecham Group Plc	Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline
PL166267B1 (pl) *	1989-11-28	1995-04-28	Syntex Inc	Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
AU7618991A (en) *	1990-05-14	1991-11-14	Syntex (U.S.A.) Inc.	Novel tricyclic compounds
US5189041A (en) *	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists

1990
- 1990-11-27 PL PL90303660A patent/PL166267B1/pl unknown
- 1990-11-27 DK DK90122689.4T patent/DK0430190T3/da active
- 1990-11-27 IE IE426990A patent/IE68434B1/en not_active IP Right Cessation
- 1990-11-27 AU AU66963/90A patent/AU642178B2/en not_active Expired
- 1990-11-27 ZA ZA909529A patent/ZA909529B/xx unknown
- 1990-11-27 EP EP90122689A patent/EP0430190B1/fr not_active Expired - Lifetime
- 1990-11-27 NZ NZ236225A patent/NZ236225A/en unknown
- 1990-11-27 FI FI905839A patent/FI98367C/fi active Protection Beyond IP Right Term
- 1990-11-27 DE DE69020694T patent/DE69020694T2/de not_active Expired - Lifetime
- 1990-11-27 PL PL90303661A patent/PL166277B1/pl unknown
- 1990-11-27 HU HU670/90A patent/HU218654B/hu active Protection Beyond IP Right Term
- 1990-11-27 IL IL9648690A patent/IL96486A/en active Protection Beyond IP Right Term
- 1990-11-27 AT AT90122689T patent/ATE124698T1/de active
- 1990-11-27 PT PT96001A patent/PT96001B/pt not_active IP Right Cessation
- 1990-11-27 CA CA002030718A patent/CA2030718C/fr not_active Expired - Lifetime
- 1990-11-27 JP JP2328764A patent/JPH0662607B2/ja not_active Expired - Fee Related
- 1990-11-27 NO NO905120A patent/NO175309C/no not_active IP Right Cessation
- 1990-11-27 PL PL90287961A patent/PL166272B1/pl unknown
- 1990-11-27 KR KR1019900019275A patent/KR970007917B1/ko not_active Expired - Lifetime
- 1990-11-27 DE DE200512000027 patent/DE122005000027I2/de active Active
- 1990-11-27 IL IL11062290A patent/IL110622A/en not_active IP Right Cessation
- 1990-11-27 ES ES90122689T patent/ES2075121T3/es not_active Expired - Lifetime
1991
- 1991-05-22 US US07/704,565 patent/US5202333A/en not_active Expired - Lifetime
1997
- 1997-03-20 HK HK36097A patent/HK36097A/en not_active IP Right Cessation
- 1997-05-08 BR BR1100680-3A patent/BR1100680A/pt active IP Right Grant
2005
- 2005-04-18 LU LU91162C patent/LU91162I2/fr unknown
- 2005-04-20 NL NL300194C patent/NL300194I1/nl unknown
- 2005-09-21 NO NO2005023C patent/NO2005023I2/no unknown

Also Published As

Publication number	Publication date
NO2005023I2 (no)	2009-10-05
AU642178B2 (en)	1993-10-14
EP0430190A3 (en)	1992-01-22
EP0430190B1 (fr)	1995-07-05
NL300194I2 (nl)	2005-07-01
FI905839L (fi)	1991-05-29
FI905839A0 (fi)	1990-11-27
HU907660D0 (en)	1991-06-28
HK36097A (en)	1997-03-27
PL166267B1 (pl)	1995-04-28
NO2005023I1 (no)	2005-10-03
EP0430190A2 (fr)	1991-06-05
IE904269A1 (en)	1991-06-05
NO175309C (no)	1994-09-28
US5202333A (en)	1993-04-13
IL96486A0 (en)	1991-08-16
NO905120L (no)	1991-05-29
IE68434B1 (en)	1996-06-12
ZA909529B (en)	1992-08-26
DE122005000027I1 (de)	2005-08-04
PT96001A (pt)	1991-09-30
FI98367B (fi)	1997-02-28
BR1100680A (pt)	2000-02-08
HU218654B (hu)	2000-10-28
PL166277B1 (pl)	1995-04-28
CA2030718C (fr)	1998-05-12
NO175309B (no)	1994-06-20
DK0430190T3 (da)	1995-08-21
ATE124698T1 (de)	1995-07-15
PL166272B1 (pl)	1995-04-28
FI98367C (fi)	1997-06-10
PT96001B (pt)	1998-01-30
DE122005000027I2 (de)	2006-03-16
DE69020694T2 (de)	1996-01-18
IL96486A (en)	1995-03-30
NO905120D0 (no)	1990-11-27
JPH0662607B2 (ja)	1994-08-17
ES2075121T3 (es)	1995-10-01
KR910009699A (ko)	1991-06-28
HUT56368A (en)	1991-08-28
NZ236225A (en)	1992-09-25
KR970007917B1 (ko)	1997-05-17
JPH03176486A (ja)	1991-07-31
AU6696390A (en)	1991-06-06
IL110622A (en)	1995-03-30
CA2030718A1 (fr)	1991-05-29
DE69020694D1 (de)	1995-08-10
PL287961A1 (en)	1991-12-02
NL300194I1 (nl)	2005-07-01

Publication	Publication Date	Title
LU91162I2 (fr)	2005-06-20	Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables.
KR900012911A (ko)	1990-09-03	흥분성 아미노산 수용기 길항질 화합물
EA200000731A1 (ru)	2001-02-26	Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
ATE219766T1 (de)	2002-07-15	N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
ATE297203T1 (de)	2005-06-15	Antithrombotische mitteln
EA200200873A1 (ru)	2003-04-24	Новые пиперазиновые производные
ATE306261T1 (de)	2005-10-15	Antithrombosemittel
EA200000391A1 (ru)	2000-12-25	Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
ES2124545T3 (es)	1999-02-01	Azolidindionas como agentes antihiperglucemicos.
EA199800794A1 (ru)	1999-04-29	Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
TR199801782T2 (xx)	1998-12-21	Kinoksalindionlar
ID25477A (id)	2000-10-05	Turunan-turunan spiropiperidin
EP0604352A3 (fr)	1995-02-08	Composés hétérocycliques substitués par un groupement aryle.
EP0604355A3 (fr)	1995-02-08	Composés hétérocycliques substitués par un groupement alkyle.
TW334428B (en)	1998-06-21	Novel benzodiazepine derivatives
DE69402703D1 (de)	1997-05-22	3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND
EA200101050A1 (ru)	2002-04-25	Замещенные бензолактамные соединения
WO1997029077A1 (fr)	1997-08-14	Derives amides substitues
ATE264320T1 (de)	2004-04-15	5-aminoalkyl- und 5-aminocarbonylsubstituierte indole